CRVL, TASR, FSL ......
CorVel (CRVL) Announces 200K Stock Buyback
********************************************************
(RTTNews) - TASER International Inc. (TASR) announced just before noon that the US District Court in the Eastern District of Louisiana granted the company's motion for summary judgment in the product liability lawsuit filed by Dardenella Gosserand against TASER.
TASER International has since spiked above Friday's narrow range on increased volume and is now up 0.25 at $9.30. The stock is trading near the middle of a one-month range.
*********************************************
(RTTNews) - Freescale Semiconductor (FSL) reported that it has shipped more than 300 million accelerometers - a major milestone in the company's long history of sensor innovation. "Freescale's acceleration sensors are in high demand for embedded systems requiring measurement of g forces, which can damage sensitive electronics components," said Demetre Kondylis, director and general manager of Freescale's Sensor & Actuator Solutions Division. The company's broad portfolio of acceleration sensor products enables embedded developers to address a diverse range of existing and emerging applications that require accurate detection of small changes in force.
***********************************************
(RTTNews) - Friday morning, Allos Therapeutics Inc. (ALTH), a biopharmaceutical company engaged in the development of small molecule drugs for cancer treatments, said it has released updated safety results from its ongoing pralatrexate or PDX Phase 1/2 clinical study. The trial was conducted in patients with relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma or NHL. PDX is a small molecule chemotherapeutic agent that reduces the DNA building enzyme, dihdrofolate reductase. The company noted that the result was presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics.
The Westminster, Colorado-based company said that the ongoing Phase 1/2 trial has been designed to assess the maximum tolerated dose, dose limiting toxicities and preliminary efficacy of PDX in patients with relapsed or refractory aggressive lymphomas. During the study the subjects enrolled were administered with 135 mg/m2 of PDX without folic acid and vitamin B12 supplementation every other week. The findings revealed increased occurrence of stomatitis in patients with notable elevations in pre-treatment homocysteine or Hcy and methylmalonic acid or MMA. Patients with less than 10 mM of Hcy and MMA showed little rise in stomatitis, while Patients with Hcy and MMA less than 200 nM did not exhibit increase in stomatitis. However, the trial showed that patients with increased Hcy and MMA who developed stomatitis with PDX did not develop advanced grade stomatitis after normalization of their Hcy and MMA with folic acid and vitamin B12 supplementation. Following these observations, when the patients were given pre-treatment with vitamin supplementation of vitamin B12 and folic acid, normalization of Hcy and MMA levels mitigated the incidence of stomatitis.
Additionally, Allos stated that a pivotal Phase 2, international, multi-center, open-label, single-arm study named PROPEL has been planned on PDX. 100 evaluable patients with relapsed or refractory PTCL who have progressed after at least one prior treatment are expected to be enrolled in the study. The study in designed with the primary endpoint of objective response rate and secondary endpoints of duration of response, progression-free survival and overall survival.
Earlier in August 2006, Allos revealed it had signed an agreement with the FDA under the Special Protocol Assessment process on the design of this pivotal Phase 2 trial. Patient enrollment at 35 centers in the U.S., Canada and Europe is expected to complete by the third quarter of 2008. PDX was awarded orphan drug designation by FDA in July 2006 for the treatment of patients with T-cell lymphoma. Peripheral T-cell lymphomas or PTCLs are a biologically diverse and uncommon group of blood cancers.
ALTH is currently trading at $4.16, up $0.01 or 0.24%, on a volume of 66,018 shares.
*********************************************
